摘要
Infection with hepatitis B virus(HBV) poses a major health threat worldwide, where the magnitude and overburden of chronic carrier state approaches 150 million chronic carriers. The prevalence of HBV is greater among dialyzed patients compared to the general population owing to their increased vulnerability to blood and its products, along with hazards posed by contaminated hemodialysis tools and devices. Anelectronic systematic search of the published literature was carried and data on the immunological riposte to hepatitis B vaccination among hemodialysis patients was extracted from relevant studies. End stage renal disease patients on hemodialysis have a lower or an absolutely negative riposte to HBV vaccine. Several means have been tried to improve this response with some success, nevertheless none have been universally adopted. Genetic investigations are foreseen to make a break through concerning HBV vaccination.
Infection with hepatitis B virus （HBV） poses a majorhealth threat worldwide, where the magnitude andoverburden of chronic carrier state approaches 150million chronic carriers. The prevalence of HBV isgreater among dialyzed patients compared to thegeneral population owing to their increased vulnerabilityto blood and its products, along with hazards posedby contaminated hemodialysis tools and devices. Anelectronic systematic search of the published literaturewas carried and data on the immunological riposte tohepatitis B vaccination among hemodialysis patientswas extracted from relevant studies. End stage renaldisease patients on hemodialysis have a lower or anabsolutely negative riposte to HBV vaccine. Severalmeans have been tried to improve this response withsome success, nevertheless none have been universallyadopted. Genetic investigations are foreseen to make abreak through concerning HBV vaccination.
